PL1850873T3 - Przeciwciała przeciwko tgfbeta - Google Patents

Przeciwciała przeciwko tgfbeta

Info

Publication number: PL1850873T3
Authority: PL; Poland
Prior art keywords: tgfbeta; antibodies
Prior art date: 2005-02-08

Application number

PL06734583T

Other languages

English (en)

Inventor

Steven R. Ledbetter

Celia P. Hart

Robert G. Holgate

Lutz U. Jermutus

Catriona L. Buchanan

Alexander R. Duncan

Donna K. Finch

Original Assignee

Genzyme Corporation

Optein, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-02-08

Filing date

2006-02-08

Publication date

2019-06-28

2006-02-08 Application filed by Genzyme Corporation, Optein, Inc. filed Critical Genzyme Corporation

2019-06-28 Publication of PL1850873T3 publication Critical patent/PL1850873T3/pl

Links

ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Urology & Nephrology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

PL06734583T 2005-02-08 2006-02-08 Przeciwciała przeciwko tgfbeta PL1850873T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US65134305P	2005-02-08	2005-02-08
PCT/US2006/004424 WO2006086469A2 (en)	2005-02-08	2006-02-08	Antibodies to tgfbeta
EP06734583.5A EP1850873B1 (en)	2005-02-08	2006-02-08	Antibodies to tgfbeta

Publications (1)

Publication Number	Publication Date
PL1850873T3 true PL1850873T3 (pl)	2019-06-28

Family

ID=36793677

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL06734583T PL1850873T3 (pl)	2005-02-08	2006-02-08	Przeciwciała przeciwko tgfbeta
PL18208382T PL3520815T3 (pl)	2005-02-08	2006-02-08	Przeciwciała przeciwko TGFBETA

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL18208382T PL3520815T3 (pl)	2005-02-08	2006-02-08	Przeciwciała przeciwko TGFBETA

Country Status (19)

Country	Link
US (11)	US7723486B2 (pl)
EP (2)	EP3520815B1 (pl)
JP (5)	JP5174466B2 (pl)
CN (3)	CN104177497B (pl)
AU (1)	AU2006213875B2 (pl)
BR (1)	BRPI0607639B1 (pl)
CA (2)	CA2930677A1 (pl)
CY (1)	CY1121424T1 (pl)
DK (1)	DK1850873T3 (pl)
ES (2)	ES2711213T3 (pl)
HU (1)	HUE042689T2 (pl)
IL (3)	IL184995A (pl)
LT (1)	LT1850873T (pl)
MX (1)	MX2007009545A (pl)
PL (2)	PL1850873T3 (pl)
PT (2)	PT3520815T (pl)
SI (1)	SI1850873T1 (pl)
TR (1)	TR201901929T4 (pl)
WO (1)	WO2006086469A2 (pl)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2607422Y2 (ja)	1990-03-16	2001-09-04	株式会社東海理化電機製作所	ウエビング巻取装置
JP2607424Y2 (ja)	1990-03-16	2001-09-04	株式会社東海理化電機製作所	ウエビング巻取装置
JP2607425Y2 (ja)	1990-03-16	2001-09-04	株式会社東海理化電機製作所	ウエビング巻取装置
JP2607423Y2 (ja)	1990-03-16	2001-09-04	株式会社東海理化電機製作所	ウエビング巻取装置
US7563874B2 (en) *	1998-08-31	2009-07-21	The Regents Of The University Of California	Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
CA2561686C (en) *	2004-03-31	2014-12-02	Genentech, Inc.	Humanized anti-tgf-beta antibodies
PT3520815T (pt) *	2005-02-08	2022-02-02	Genzyme Corp	Anticorpos contra tgfbeta
DK2918288T3 (da) *	2006-10-03	2017-11-27	Genzyme Corp	Anvendelse af TGF-beta-antagonister til behandling af spædbørn med risiko for udvikling af bronkopulmonal dysplasi
MX2009009079A (es) *	2007-02-23	2009-08-31	Schering Corp	Anticuerpos anti-il-23p19 de ingenieria.
CA2678863A1 (en) *	2007-02-23	2008-08-28	Schering Corporation	Engineered anti-il-23p19 antibodies
CA2680741A1 (en) *	2007-03-22	2009-01-15	The Regents Of The University Of California	Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US9000131B2 (en) *	2008-07-31	2015-04-07	The Regents Of The University Of California	Antibodies that neutralize botulinum neurotoxins
UA112050C2 (uk) *	2008-08-04	2016-07-25	БАЄР ХЕЛСКЕР ЛЛСі	Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
KR20160005143A (ko)	2009-05-13	2016-01-13	젠자임 코포레이션	항-인간 ｃｄ52 면역글루불린
SG183443A1 (en)	2010-03-01	2012-09-27	Bayer Healthcare Llc	Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
SI3117709T1 (sl)	2010-03-12	2018-12-31	Genzyme Corporation	Kombinirana terapija za zdravljenje raka dojke
WO2012047427A2 (en)	2010-08-31	2012-04-12	The Regents Of The University Of California	Antibodies for botulinum neurotoxins
US20130330352A1 (en) *	2010-09-01	2013-12-12	Genzyme Corporation	Treatment of myocardial infarction using tgf beta antagonists
CA2817250A1 (en)	2010-11-18	2012-05-24	The General Hospital Corporation	Novel compositions and uses of anti-hypertension agents for cancer therapy
AR084141A1 (es)	2010-11-19	2013-04-24	Imai Toshio	Anticuerpos neutralizadores anti-ccl20
AU2012261933B2 (en) *	2011-06-03	2017-06-15	Xoma Technology Ltd.	Antibodies specific for TGF-beta
WO2013014262A1 (en)	2011-07-27	2013-01-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosing and treating myhre syndrome
BR112014009789A2 (pt)	2011-10-26	2017-04-25	Seattle Children's Res Inst	cisteamina no tratamento da doença fibrótica
US9782452B2 (en)	2011-11-22	2017-10-10	Cornell University	Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling
US10259626B2 (en)	2012-03-08	2019-04-16	Selig Sealing Products, Inc.	Container sealing member with protected security component and removal tab
DK2822592T3 (en)	2012-03-08	2018-10-15	Ludwig Institute For Cancer Res Limited	TGF-1-SPECIFIC ANTIBODIES AND PROCEDURES AND APPLICATIONS THEREOF
KR102258457B1 (ko) *	2013-03-11	2021-05-31	젠자임 코포레이션	조작된 항-tgf-베타 항체 및 항원-결합 단편
CA3184040A1 (en)	2013-03-14	2014-10-02	The Brigham And Women's Hospital, Inc.	Compositions and methods for epithelial stem cell expansion comprising a wnt agonist and a histone deacetylase inhibitor
PL3312195T3 (pl) *	2013-03-20	2020-04-30	Genzyme Corporation	Sposoby leczenia wrodzonej łamliwości kości
CA2911514A1 (en)	2013-05-06	2014-11-13	Scholar Rock, Inc.	Compositions and methods for growth factor modulation
CN105658672A (zh)	2013-08-22	2016-06-08	阿塞勒隆制药公司	TGF-β受体II型变体及其用途
WO2015172746A1 (en) *	2014-05-16	2015-11-19	Wellhead Biological Technology Corp.	Use of ginsenoside m1 for inhibiting renal fibrosis
WO2016037016A1 (en)	2014-09-03	2016-03-10	The Brigham And Women's Hospital, Inc.	Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
MX389663B (es)	2014-10-14	2025-03-20	Novartis Ag	Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
CA2971186A1 (en)	2014-12-15	2016-06-23	The Regents Of The University Of California	Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
US11253546B2 (en)	2014-12-15	2022-02-22	The Regents Of The University Of California	Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20
WO2016115345A1 (en)	2015-01-14	2016-07-21	The Brigham And Women's Hospital,	Treatment of cancer with anti-lap monoclonal antibodies
JP6901400B2 (ja)	2015-04-03	2021-07-14	ゾーマテクノロジーリミテッド	ＴＧＦ−β及びＰＤ−１の阻害物質を使用する癌の治療法
EP3307772B1 (en)	2015-06-12	2020-09-09	Ludwig Institute For Cancer Research Limited	Tgf-beta 3 specific antibodies and methods and uses thereof
TW201718010A (zh) *	2015-06-19	2017-06-01	健臻公司	治療原發性局部節段性腎小球硬化症之方法
DK3317301T3 (da)	2015-07-29	2021-06-28	Immutep Sas	Kombinationsterapier omfattende antistofmolekyler mod lag-3
US20180222982A1 (en)	2015-07-29	2018-08-09	Novartis Ag	Combination therapies comprising antibody molecules to pd-1
EP3878465A1 (en)	2015-07-29	2021-09-15	Novartis AG	Combination therapies comprising antibody molecules to tim-3
CN116327952A (zh)	2015-08-04	2023-06-27	阿塞勒隆制药公司	用于治疗骨髓增生性病症的方法
RS64053B1 (sr)	2015-10-30	2023-04-28	Univ California	Polipeptidi koji reaguju na transformišući faktor rasta – beta i postupci za njihovu upotrebu
EP3389712B1 (en)	2015-12-17	2024-04-10	Novartis AG	Antibody molecules to pd-1 and uses thereof
US11433136B2 (en)	2015-12-18	2022-09-06	The General Hospital Corporation	Polyacetal polymers, conjugates, particles and uses thereof
AU2017205194A1 (en)	2016-01-08	2018-07-19	Massachusetts Institute Of Technology	Production of differentiated enteroendocrine cells and insulin producing cells
US11305010B2 (en) *	2016-01-21	2022-04-19	The Scripps Research Institute	Synthetic opioid vaccine
US10213511B2 (en)	2016-03-02	2019-02-26	Frequency Therapeutics, Inc.	Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en)	2016-03-02	2022-03-01	Frequency Therapeutics, Inc.	Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en)	2016-03-02	2019-02-12	Frequency Therapeutics, Inc.	Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
EP4169942A1 (en) *	2016-03-11	2023-04-26	Scholar Rock, Inc.	Tgfbeta1-binding immunoglobulins and use thereof
CA3024465A1 (en)	2016-05-17	2017-11-23	Genentech, Inc.	Stromal gene signatures for diagnosis and use in immunotherapy
GB201610044D0 (en) *	2016-06-08	2016-07-20	Ucb Biopharma Sprl	Antibodies
CA3033614A1 (en) *	2016-08-11	2018-02-15	Precithera, Inc.	Tgf-.beta. antagonist conjugates
JP2019530440A (ja)	2016-09-02	2019-10-24	ザリージェンツオブザユニバーシティオブカリフォルニア	インターロイキン６受容体α結合単鎖可変断片を含む方法および組成物
WO2018043734A1 (en) *	2016-09-05	2018-03-08	Chugai Seiyaku Kabushiki Kaisha	Anti-tgf-beta 1 antibodies and methods of use
EP3551047A1 (en)	2016-12-07	2019-10-16	Progenity, Inc.	Gastrointestinal tract detection methods, devices and systems
CN110392686A (zh)	2016-12-30	2019-10-29	频率治疗公司	1h-吡咯-2,5-二酮化合物以及使用它们来诱导干/祖支持细胞自我更新的方法
US20180207267A1 (en)	2017-01-06	2018-07-26	Scholar Rock, Inc.	Isoform-specific, context-permissive tgfb1 inhibitors and use thereof
EA201991729A1 (ru)	2017-01-20	2019-12-30	Санофи	Антитела к tgf-бета и их применение
TW202506185A (zh)	2017-01-20	2025-02-16	法商賽諾菲公司	抗TGF-β抗體及其用途
AR110755A1 (es) *	2017-01-20	2019-05-02	Genzyme Corp	Anticuerpos dirigidos a hueso
DK3628049T3 (da)	2017-05-04	2023-08-14	Acceleron Pharma Inc	Tgf-beta-receptortype-ii-fusionsproteiner og anvendelser deraf
WO2018237173A1 (en)	2017-06-22	2018-12-27	Novartis Ag	Antibody molecules to cd73 and uses thereof
EP3641812A1 (en)	2017-06-22	2020-04-29	Novartis AG	Antibody molecules to cd73 and uses thereof
EP3694552A1 (en)	2017-10-10	2020-08-19	Tilos Therapeutics, Inc.	Anti-lap antibodies and uses thereof
AU2018359967A1 (en)	2017-11-06	2020-04-23	Genentech, Inc.	Diagnostic and therapeutic methods for cancer
AU2018368731A1 (en)	2017-11-16	2020-05-14	Novartis Ag	Combination therapies
TW201925782A (zh)	2017-11-30	2019-07-01	瑞士商諾華公司	靶向bcma之嵌合抗原受體及其用途
TWI823906B (zh)	2018-03-09	2023-12-01	美商艾吉納斯公司	抗-cd73 抗體及其使用方法
US20210147547A1 (en)	2018-04-13	2021-05-20	Novartis Ag	Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
TWI869346B (zh)	2018-05-30	2025-01-11	瑞士商諾華公司	Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
US20210214459A1 (en)	2018-05-31	2021-07-15	Novartis Ag	Antibody molecules to cd73 and uses thereof
TWI848951B (zh)	2018-06-01	2024-07-21	瑞士商諾華公司	針對ｂｃｍａ之結合分子及其用途
WO2019246317A1 (en)	2018-06-20	2019-12-26	Progenity, Inc.	Treatment of a disease or condition in a tissue originating from the endoderm
AR116109A1 (es)	2018-07-10	2021-03-31	Novartis Ag	Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
US20210155708A1 (en) *	2018-07-10	2021-05-27	Sanofi	Combination therapies against cancer targeting cd38 and tgf-beta
PT3677278T (pt)	2018-07-11	2022-02-03	Scholar Rock Inc	Inibidores seletivos da isoforma tgfbeta1 e sua utilização
US20210340238A1 (en)	2018-07-11	2021-11-04	Scholar Rock, Inc.	TGFß1 INHIBITORS AND USE THEREOF
JP7540994B2 (ja)	2018-07-11	2024-08-27	スカラーロックインコーポレイテッド	高親和性のアイソフォーム選択的ＴＧＦβ１阻害剤、およびその使用
WO2020021465A1 (en)	2018-07-25	2020-01-30	Advanced Accelerator Applications (Italy) S.R.L.	Method of treatment of neuroendocrine tumors
US11162071B2 (en)	2018-08-17	2021-11-02	Frequency Therapeutics, Inc.	Compositions and methods for generating hair cells by upregulating JAG-1
WO2020037326A1 (en)	2018-08-17	2020-02-20	Frequency Therapeutics, Inc.	Compositions and methods for generating hair cells by downregulating foxo
NZ772550A (en)	2018-08-30	2025-08-29	Immunitybio Inc	Multi-chain chimeric polypeptides and uses thereof
CN120535649A (zh)	2018-08-30	2025-08-26	免疫生物公司	单链嵌合多肽和其用途
WO2020076969A2 (en)	2018-10-10	2020-04-16	Tilos Therapeutics, Inc.	Anti-lap antibody variants and uses thereof
US20210388074A1 (en)	2018-11-05	2021-12-16	Ludwig Institute For Cancer Research Ltd.	Humanized and variant tgf-beta3 specific antibodies and methods and uses thereof
CN113613725B (zh)	2018-11-05	2025-09-23	路德维格癌症研究所有限公司	人源化和变体TGF-β1特异性抗体及其方法和用途
CN116726362A (zh)	2018-11-19	2023-09-12	比奥拉治疗股份有限公司	用生物治疗剂治疗疾病的方法和装置
WO2020128972A1 (en)	2018-12-20	2020-06-25	Novartis Ag	Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EA202192130A1 (ru)	2019-01-30	2021-12-28	Сколар Рок, Инк.	Специфичные к ltbp-комплексу ингибиторы tgf и их применение
ES2982474T3 (es)	2019-02-15	2024-10-16	Novartis Ag	Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
ES3032659T3 (en)	2019-02-15	2025-07-23	Novartis Ag	3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US20220177978A1 (en)	2019-04-02	2022-06-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of predicting and preventing cancer in patients having premalignant lesions
KR20220035394A (ko)	2019-06-21	2022-03-22	에이치씨더블유 바이올로직스, 인크.	다중-사슬 키메라 폴리펩티드 및 이의 용도
US20210032322A1 (en) *	2019-08-01	2021-02-04	Vaccinex, Inc.	Combined inhibition of semaphorin-4d and tgf-beta and compositions therefor
TW202124446A (zh)	2019-09-18	2021-07-01	瑞士商諾華公司	與ｅｎｔｐｄ２抗體之組合療法
US20220348651A1 (en)	2019-09-18	2022-11-03	Novartis Ag	Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
CN114728072A (zh)	2019-10-23	2022-07-08	库尔生物制药有限公司	TGF-β多肽
CN115666704B (zh)	2019-12-13	2025-09-26	比特比德科有限责任公司	用于将治疗剂递送至胃肠道的可摄取装置
MX2022007759A (es)	2019-12-20	2022-07-19	Novartis Ag	Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
CN115190812A (zh)	2020-01-11	2022-10-14	供石公司	TGFβ抑制剂及其用途
WO2021163298A1 (en)	2020-02-11	2021-08-19	HCW Biologics, Inc.	Methods of activating regulatory t cells
AU2021220870A1 (en)	2020-02-11	2022-08-04	Immunitybio, Inc.	Methods of treating age-related and inflammatory diseases
KR20220140535A (ko)	2020-02-11	2022-10-18	에이치씨더블유 바이올로직스, 인크.	크로마토그래피 수지 및 이의 용도
TWI867190B (zh)	2020-03-19	2024-12-21	美商建南德克公司	同功型選擇性抗-TGF-β抗體及其使用方法
US12024545B2 (en)	2020-06-01	2024-07-02	HCW Biologics, Inc.	Methods of treating aging-related disorders
MX2022015852A (es)	2020-06-23	2023-01-24	Novartis Ag	Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
US20230321285A1 (en)	2020-08-31	2023-10-12	Advanced Accelerator Applications International Sa	Method of treating psma-expressing cancers
EP4204020A1 (en)	2020-08-31	2023-07-05	Advanced Accelerator Applications International S.A.	Method of treating psma-expressing cancers
AU2021373366A1 (en)	2020-11-06	2023-06-01	Novartis Ag	Cd19 binding molecules and uses thereof
JP2023548346A (ja) *	2020-11-11	2023-11-16	ハン，ハック	アクチビン／ｔｇｆ－ベータおよびｒａｎｋｌの二機能性アンタゴニストならびにその使用
AU2021388155A1 (en)	2020-11-25	2023-06-15	Catamaran Bio, Inc.	Cellular therapeutics engineered with signal modulators and methods of use thereof
JP2024505049A (ja)	2021-01-29	2024-02-02	ノバルティスアーゲー	抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用
KR20230146032A (ko)	2021-02-15	2023-10-18	다케다 야쿠힌 고교 가부시키가이샤	Tgf-b 신호전달을 조절하기 위한 세포 치료 조성물 및 방법
US12180521B2 (en)	2021-02-19	2024-12-31	Theripion, Inc.	Paraoxonase fusion polypeptides and related compositions and methods
TW202304979A (zh)	2021-04-07	2023-02-01	瑞士商諾華公司	抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CN112940119B (zh) *	2021-04-26	2022-05-20	北京芳渟阳生生物科技有限公司	一种单克隆抗体及其与间充质干细胞外泌体的联合应用
AR125874A1 (es)	2021-05-18	2023-08-23	Novartis Ag	Terapias de combinación
WO2022256723A2 (en)	2021-06-03	2022-12-08	Scholar Rock, Inc.	Tgf-beta inhibitors and therapeutic use thereof
CA3227318A1 (en)	2021-08-11	2023-02-16	HCW Biologics, Inc.	Multi-chain chimeric polypeptides and use thereof in the treatment of liver diseases
WO2023080900A1 (en)	2021-11-05	2023-05-11	Genentech, Inc.	Methods and compositions for classifying and treating kidney cancer
KR20250004757A (ko)	2022-04-13	2025-01-08	이뮤니티바이오, 인크.	신경염증성 장애의 치료에 사용하기 위한 다중-사슬 키메라 폴리펩티드
KR20250004747A (ko)	2022-04-13	2025-01-08	이뮤니티바이오, 인크.	생체 시계 유전자 장애의 치료에 사용하기 위한 다중-사슬 키메라 폴리펩티드
CN119213034A (zh)	2022-05-17	2024-12-27	苏州创胜医药集团有限公司	双功能蛋白质及其制剂和用途
EP4599088A1 (en)	2022-10-05	2025-08-13	Genentech, Inc.	Methods and compositions for classifying and treating lung cancer
EP4599089A1 (en)	2022-10-05	2025-08-13	Genentech, Inc.	Methods and compositions for classifying and treating bladder cancer
KR20250133913A (ko) *	2023-01-09	2025-09-09	베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드	TGFβ1 결합 분자, GARP-TGFβ1 결합 분자 및 이의 의학적 용도
EP4509522A1 (en)	2023-08-16	2025-02-19	Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft	A tgfbeta switch receptor, a nucleic acid encoding it, cells and pharmaceutical compositions comprising the same
WO2025058919A1 (en) *	2023-09-12	2025-03-20	Lyell Immunopharma, Inc.	Bispecific chimeric antigen receptors and use thereof
WO2025140212A1 (en) *	2023-12-26	2025-07-03	Laekna Therapeutics Shanghai Co., Ltd.	Multispecific binding agents comprising anti-fibroblast activation protein (fap) antibodies and one or more monovalent ligand traps and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2056642B (en)	1979-08-08	1983-05-11	Dawson Int	Radio frequency drying of textile material
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
JPS61134325A (ja)	1984-12-04	1986-06-21	Teijin Ltd	ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5571714A (en) *	1988-12-22	1996-11-05	Celtrix Pharmaceuticals, Inc.	Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US20040028682A1 (en) *	1989-09-29	2004-02-12	Border Wayne A.	Inhibiting transforming growth factor beta to prevent accumulation of extracellular matrix
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
EP0561921A1 (en)	1990-12-10	1993-09-29	Panama Engineering Pty Limited	Fork-lift attachment
EP0590058B1 (en)	1991-06-14	2003-11-26	Genentech, Inc.	HUMANIZED Heregulin ANTIBODy
US5565332A (en) *	1991-09-23	1996-10-15	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
JP3540315B2 (ja)	1991-09-23	2004-07-07	メディカルリサーチカウンシル	キメラ抗体の製造−組合せアプローチ
US5269388A (en)	1991-11-12	1993-12-14	Stress-Tek, Inc.	Weighing bed
US5543143A (en) *	1992-03-06	1996-08-06	Corixa Corporation	Method for activating macrophages/monocytes
EP0672142B1 (en)	1992-12-04	2001-02-28	Medical Research Council	Multivalent and multispecific binding proteins, their manufacture and use
US5824655A (en) *	1995-02-15	1998-10-20	The University Of Utah	Anti-transforming growth factor-β gene therapy
GB9601081D0 (en)	1995-10-06	1996-03-20	Cambridge Antibody Tech	Specific binding members for human transforming growth factor beta;materials and methods
DE69721548T2 (de)	1996-02-09	2004-04-01	Abbott Laboratories(Bermuda)Ltd.	HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN
CN1330377C (zh)	1996-03-10	2007-08-08	明治乳业株式会社	用于治疗变态反应疾病的基于肽的免疫治疗剂
PT1137941E (pt)	1998-12-10	2009-10-15	Brystol Myers Squibb Company	Esqueletos de proteínas para compostos miméticos de anticorpos e outras proteínas de ligação
AU3921600A (en) *	1999-03-25	2000-10-09	Abbott Gmbh & Co. Kg	Human antibodies that bind human il-12 and methods for producing
US6492497B1 (en) *	1999-04-30	2002-12-10	Cambridge Antibody Technology Limited	Specific binding members for TGFbeta1
ATE414151T1 (de)	2000-03-03	2008-11-15	Cambridge Antibody Tech	Antikörper gegen eotaxin und deren verwendung
US20030224501A1 (en) *	2000-03-17	2003-12-04	Young Paul E.	Bone morphogenic protein polynucleotides, polypeptides, and antibodies
AU2002226366B2 (en) *	2000-12-06	2007-03-22	Laboratoires Serono Sa	Use of SARP-1 for the treatment and/or prevention of scleroderma
AU2003257666A1 (en) *	2002-08-23	2004-03-11	Kirin Beer Kabushiki Kaisha	COMPOUND HAVING TGFss INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME
WO2004098637A1 (en) *	2003-04-30	2004-11-18	Genzyme Corporation	Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
EP1646655A2 (en)	2003-07-09	2006-04-19	Eli Lilly And Company	Tgf-beta1 ligands
GB0407315D0 (en) *	2003-07-15	2004-05-05	Cambridge Antibody Tech	Human antibody molecules
JP2005112812A (ja) *	2003-10-09	2005-04-28	Zeria Pharmaceut Co Ltd	リン酸化部位特異的抗体及びそれを用いたスクリーニング方法
JP4842834B2 (ja)	2003-12-09	2011-12-21	ノボザイムス，インコーポレイティド	糸状菌株における遺伝子の発現を排除するか又は低めるための方法
CA2561686C (en)	2004-03-31	2014-12-02	Genentech, Inc.	Humanized anti-tgf-beta antibodies
KR100749566B1 (ko) *	2004-04-21	2007-08-16	이화여자대학교 산학협력단	Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
PT3520815T (pt) *	2005-02-08	2022-02-02	Genzyme Corp	Anticorpos contra tgfbeta
ITMI20110376A1 (it)	2011-03-10	2012-09-11	Wilic Sarl	Aerogeneratore raffreddato a fluido
DE102011078333A1 (de)	2011-06-29	2013-01-03	Siemens Aktiengesellschaft	Überspannungsableiter

2006
- 2006-02-08 PT PT182083824T patent/PT3520815T/pt unknown
- 2006-02-08 BR BRPI0607639-4A patent/BRPI0607639B1/pt active IP Right Grant
- 2006-02-08 CA CA2930677A patent/CA2930677A1/en not_active Abandoned
- 2006-02-08 CN CN201410331821.3A patent/CN104177497B/zh active Active
- 2006-02-08 ES ES06734583T patent/ES2711213T3/es active Active
- 2006-02-08 PL PL06734583T patent/PL1850873T3/pl unknown
- 2006-02-08 CA CA2597098A patent/CA2597098C/en active Active
- 2006-02-08 WO PCT/US2006/004424 patent/WO2006086469A2/en not_active Ceased
- 2006-02-08 PL PL18208382T patent/PL3520815T3/pl unknown
- 2006-02-08 HU HUE06734583A patent/HUE042689T2/hu unknown
- 2006-02-08 MX MX2007009545A patent/MX2007009545A/es active IP Right Grant
- 2006-02-08 DK DK06734583.5T patent/DK1850873T3/en active
- 2006-02-08 TR TR2019/01929T patent/TR201901929T4/tr unknown
- 2006-02-08 SI SI200632315T patent/SI1850873T1/sl unknown
- 2006-02-08 AU AU2006213875A patent/AU2006213875B2/en active Active
- 2006-02-08 LT LTEP06734583.5T patent/LT1850873T/lt unknown
- 2006-02-08 JP JP2007554339A patent/JP5174466B2/ja active Active
- 2006-02-08 CN CN201410332384.7A patent/CN104151427B/zh active Active
- 2006-02-08 PT PT06734583T patent/PT1850873T/pt unknown
- 2006-02-08 US US11/350,906 patent/US7723486B2/en active Active
- 2006-02-08 EP EP18208382.4A patent/EP3520815B1/en active Active
- 2006-02-08 ES ES18208382T patent/ES2905923T3/es active Active
- 2006-02-08 CN CNA2006800088389A patent/CN101163502A/zh active Pending
- 2006-02-08 EP EP06734583.5A patent/EP1850873B1/en active Active
2007
- 2007-01-30 US US11/700,711 patent/US20070134246A1/en not_active Abandoned
- 2007-01-30 US US11/700,684 patent/US20070264255A1/en not_active Abandoned
- 2007-08-02 IL IL184995A patent/IL184995A/en active IP Right Grant
2010
- 2010-03-15 US US12/724,347 patent/US8383780B2/en active Active
2012
- 2012-08-16 JP JP2012180580A patent/JP5726140B2/ja active Active
- 2012-09-13 US US13/615,388 patent/US8591901B2/en active Active
2013
- 2013-04-14 IL IL225752A patent/IL225752A/en active IP Right Grant
- 2013-10-21 US US14/059,241 patent/US9090685B2/en active Active
2014
- 2014-09-22 JP JP2014192304A patent/JP6005703B2/ja active Active
2015
- 2015-04-09 US US14/682,975 patent/US9481726B2/en active Active
2016
- 2016-03-30 JP JP2016067713A patent/JP6341945B2/ja active Active
- 2016-09-28 US US15/278,819 patent/US10174108B2/en active Active
2017
- 2017-08-01 JP JP2017148818A patent/JP6463807B2/ja active Active
- 2017-10-16 IL IL255078A patent/IL255078B/en active IP Right Grant
2018
- 2018-11-21 US US16/197,802 patent/US10781252B2/en active Active
2019
- 2019-02-26 CY CY20191100235T patent/CY1121424T1/el unknown
2020
- 2020-08-19 US US16/997,365 patent/US20210061897A1/en not_active Abandoned
2022
- 2022-09-16 US US17/932,950 patent/US20230078449A1/en active Pending

Also Published As

Publication number	Publication date
US9481726B2 (en)	2016-11-01
EP3520815B1 (en)	2021-11-17
JP6463807B2 (ja)	2019-02-06
JP2008529503A (ja)	2008-08-07
CN101163502A (zh)	2008-04-16
US20070264255A1 (en)	2007-11-15
DK1850873T3 (en)	2019-03-18
PT3520815T (pt)	2022-02-02
CN104151427A (zh)	2014-11-19
JP5726140B2 (ja)	2015-05-27
AU2006213875A1 (en)	2006-08-17
US10174108B2 (en)	2019-01-08
IL225752A0 (en)	2013-06-27
US10781252B2 (en)	2020-09-22
US20130243788A1 (en)	2013-09-19
US20060251658A1 (en)	2006-11-09
SI1850873T1 (sl)	2019-05-31
US20110008364A1 (en)	2011-01-13
BRPI0607639A2 (pt)	2009-09-22
EP3520815A1 (en)	2019-08-07
US9090685B2 (en)	2015-07-28
US20070134246A1 (en)	2007-06-14
US20190177406A1 (en)	2019-06-13
WO2006086469A2 (en)	2006-08-17
BRPI0607639B1 (pt)	2022-04-05
JP2015003917A (ja)	2015-01-08
TR201901929T4 (tr)	2019-03-21
JP2017217003A (ja)	2017-12-14
PT1850873T (pt)	2019-02-19
US20230078449A1 (en)	2023-03-16
EP1850873A4 (en)	2012-06-13
US20150284456A1 (en)	2015-10-08
CY1121424T1 (el)	2020-05-29
ES2905923T3 (es)	2022-04-12
IL225752A (en)	2017-10-31
IL255078A0 (en)	2017-12-31
US20170066821A1 (en)	2017-03-09
HK1201859A1 (en)	2015-09-11
JP6341945B2 (ja)	2018-06-13
CN104177497B (zh)	2018-01-16
US7723486B2 (en)	2010-05-25
CA2597098A1 (en)	2006-08-17
JP2013031444A (ja)	2013-02-14
CA2597098C (en)	2016-08-02
US8383780B2 (en)	2013-02-26
HK1201860A1 (en)	2015-09-11
JP5174466B2 (ja)	2013-04-03
JP6005703B2 (ja)	2016-10-12
PL3520815T3 (pl)	2022-04-11
US20210061897A1 (en)	2021-03-04
IL255078B (en)	2021-01-31
HUE042689T2 (hu)	2019-07-29
US8591901B2 (en)	2013-11-26
EP1850873B1 (en)	2018-11-28
CN104177497A (zh)	2014-12-03
EP1850873A2 (en)	2007-11-07
AU2006213875B2 (en)	2010-08-19
LT1850873T (lt)	2019-04-10
ES2711213T3 (es)	2019-04-30
WO2006086469A3 (en)	2007-04-19
US20140127230A1 (en)	2014-05-08
JP2016128512A (ja)	2016-07-14
IL184995A0 (en)	2007-12-03
MX2007009545A (es)	2008-03-11
CA2930677A1 (en)	2006-08-17
CN104151427B (zh)	2017-09-08
IL184995A (en)	2013-04-30

Publication	Publication Date	Title
SI1850873T1 (sl)	2019-05-31	Protitelesa proti TGFBETA
IL189599A0 (en)	2008-08-07	Methods to enhance chemotherapy
IL191340A (en)	2015-08-31	Monoclonal antibodies against e8o
IL186739A0 (en)	2008-02-09	Antibodies to myostatin
ZA200900395B (en)	2010-01-27	Antibodies directed to +-Vß6 and uses thereof
IL187106A (en)	2015-10-29	Sclerostin binds antibody
IL190472A0 (en)	2008-11-03	Anti-glypican-3 antibody
ZA200805850B (en)	2009-04-29	Anti-ILT7 antibody
IL185366A0 (en)	2008-02-09	Antibody
PT2011869E (pt)	2014-07-09	Novo anticorpo anti-cd98
EP2125890A4 (en)	2010-04-07	ANTIBODIES AGAINST PHOSPHORYLATED IRAQ4
GB0517487D0 (en)	2005-10-05	Antibodies
EP1869192A4 (en)	2010-10-20	FRAME MIXTURE OF ANTIBODIES
IL172276A0 (en)	2006-04-10	Cross-reference to related application
EP1896047A4 (en)	2009-07-22	ANTI-GFRALPHA3 ANTIBODIES
GB0505489D0 (en)	2005-04-20	Antibodies
ZA200804254B (en)	2009-01-28	Human monoclonal antibodies to O8E
GB0512278D0 (en)	2005-07-27	Antibodies
GB0505054D0 (en)	2005-04-20	Antibodies
GB0517718D0 (en)	2005-10-05	Further improvement to brikmat
GB2423802B (en)	2009-05-06	Improvements relating to vacuum-brake-boosters
GB0500847D0 (en)	2005-02-23	Claims to be made
GB0519883D0 (en)	2005-11-09	Antibodies
GB0413163D0 (en)	2004-07-14	Improvements to signware
GB0500400D0 (en)	2005-02-16	Antibody